Pulmonology Department, University Clinical Hospital of Santiago, Santiago de Compostela, Spain.
Interdisciplinary Research Group in Pulmonology, Health Research Institute of Santiago de Compostela (IDIS), Santiago de Compostela, Spain.
Clin Respir J. 2022 Nov;16(11):768-773. doi: 10.1111/crj.13534. Epub 2022 Aug 26.
Inhaled antibiotics reduce the frequency of exacerbations. The objective was to assess the efficacy of inhaled ceftazidime in patients with non-cystic fibrosis bronchiectasis (NCFB) and concomitant chronic bronchial infection (CBI) caused by potentially pathogenic microorganisms (PPM) other than Pseudomonas aeruginosa (PA).
Quasi-experimental study in 21 patients with exacerbations who developed CBI by a PPM other than PA.
Bacterial infection was resolved in 85.7% patients. Rehospitalizations, length of hospital stay, moderate exacerbations and blood levels of CRP decreased significantly. In addition, SGRQ questionnaire also decreased more than 4 points in 57.1% of the patients.
The results suggest that inhaled ceftazidime in NCFB unrelated to PA is a plausible alternative to the standard therapies used in clinical practice.
吸入抗生素可降低恶化频率。目的是评估头孢他啶吸入剂在非囊性纤维化支气管扩张症（NCFB）和由除铜绿假单胞菌（PA）以外的潜在致病微生物（PPM）引起的同时存在的慢性支气管感染（CBI）患者中的疗效。
对 21 例因除 PA 以外的 PPM 引起 CBI 的恶化患者进行准实验研究。
85.7%的患者细菌感染得到解决。再住院率、住院时间、中度恶化和 CRP 血液水平显著降低。此外，SGRQ 问卷在 57.1%的患者中也降低了超过 4 分。
结果表明，与 PA 无关的 NCFB 中使用头孢他啶吸入剂是临床实践中标准治疗的合理替代方案。
